Anticoagulation with Novastan® (Argatroban) in patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome

Seminars in Thrombosis and Hemostasis

Volumn 23, Issue 2, 1997, Pages 197-202

  Lewis, Bruce E ^a   Walenga, Jeanine M ^a   Wallis, Diane E ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Anticoagulation; Argatroban; Heparin induced thrombocytopenia thrombosis; Thrombin inhibitor

Indexed keywords

ARGATROBAN; HEPARIN; THROMBIN INHIBITOR; ANTIBODY; ANTITHROMBIN; PIPECOLIC ACID DERIVATIVE;

MORTALITY; PRIORITY JOURNAL; SHORT SURVEY; THROMBOCYTOPENIA; THROMBOSIS; BLOOD; CHEMICALLY INDUCED DISORDER; HUMAN; IMMUNOLOGY; REVIEW; SYNDROME;

ANTIBODIES; ANTITHROMBINS; HEPARIN; HUMANS; PIPECOLIC ACIDS; SYNDROME; THROMBOCYTOPENIA; THROMBOSIS;

EID: 0030611555     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-996091     Document Type: Short Survey

References (35)

1. Chong BH, WR Pitney, PA Castaldi: Heparin-induced thrombocytopenia: Association of thrombotic complications with heparindependent IgG antibody that induces thromboxane synthesis and platelet aggregation. Lancet 2:1246, 1982.
2. Amiral J, F Bridey, M Dreyfus, AM Vissac, E Fressinaud, M Wolf, D Meyer: Platelet factor 4 complexed to heparin is the target for antibodies generated in hepann-induced thrombocytopenia. Thromb Haemostas 68:95-96, 1992.
3. Chong BH, RL Pilgrim, MA Cooley, CN Chesterman: Increased expression of platelet IgG Fc receptors in immune heparin-induced thrombocytopenia. Blood 81:988-993, 1993.
4. Greinacher A, S Alban, V Dummel, G Franz, C Mueller-Eckhardt: Characterization of the structural requirements for a carbohydrate based anticoagulant with a reduced risk of inducing the immunological type of heparin-associated thrombocytopenia. Thromb Haemostas 74:886-892, 1995.
5. Suh JS, RH Aster, GP Visentin: Affinity-purified antibodies from patients with heparin-induced thrombocytopenia (HITP) recognize multiple sites on heparin: PF4 complexes and react with platelets and endothelial cells. Blood 86(Suppl 1):444 (Abstr), 1995.
6. Visentin GP, SE Ford, JP Scott, RH Aster: Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest 93:81-88, 1994.
7. Messmore HL, S Nand, J Godwin: Heparin-induced thrombocytopenia and platelet activation in cardiovascular surgery. In: Pifarré R (Ed): Anticoagulation, Hemostasis, and Blood Preservation in Cardiovascular Surgery, Hunley & Belfus, Philadelphia, 1993, pp 185-199.
8. Wallis DK, BB Lewis, R Pifarré, PJ Scanlon: Active surveillance for heparin-induced thrombocytopenia or thromboembolism. Chest 106:120S, 1994. Abstract.
9. Warkentin TE, MN Levine, J Hirsh, P Horsewood, RS Roberts, M Gent, JG Kelton. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 332:1330-1335, 1995.
10. Ahhyankar V. P Kouides, P Phatak: Heparin-induced thrombocytopenia is a cause of thromboembolism following coronary bypass surgery. Blood 86(Suppl 1):846 (Abstr 3372), 1995.
11. Chong BH, J Burgess, F Ismail: The clinical usefulness of the platelet aggregation test for the diagnosis of heparin-induced thrombocytopenia. Thromb Haemostas 69:344-350, 1993.
12. Raible MD, H Wolf, F Leya, D Hoppensteadt, E Galbraith, JM Walenga, J Fareed: Post-PTCA generation of hep-PF4 antibodies is associated with previous exposure to unfractionated heparin. Studies with the chronic administration of LMWH. Blood 86 (Suppl 1):551 (Abstr 2191), 1995.
13. 14C-serotonin release, anti-heparin/platelet factor 4 antibodies, platelet aggregometry, and flow cytometric methods. Blood 88(Suppl 1):S317 (Abstr 1256), 1996.
14. Warkentin TE, CPM Hayward, LK Boshkov, AV Sanots, Jl Sheppard, AP Bode, JG Kelton: Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: An explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood 84:3691-3699, 1994.
15. Siljander P, O Carpen, R Lassila: Platelet-derived microparticles associate with fibrin during thrombosis. Blood 87:4651-4663, 1996.
16. Lewis BE, FS Leya, D Wallis, E Grassman: Failure of ancrod in the treatment of heparin-induced arterial thrombosis. Can J Cardiol 10:559-561, 1994.
17. Alving B, C Bolan, C Krishnamurti, T Reid III: Pharmacology and mechanism of action of ancrod; potential for inducing thrombosis. Blood 69:798-803 (Letter to the Editor), 1987.
18. Walenga JM, MJ Koza, BE Lewis, R Pifarré: Relative heparin-induced thrombocytopenic potential of low molecular weight heparins and new antithrombotic agents. Clin Appl Thromb Hemostas 2(Suppl 1):S21-S27, 1996.
19. Eichinger S, PA Kyrle, B Brenner, B Wagner, S Kapiotis, K Lechner, HC Korninger: Thrombocytopenia associated with low-molecular-weight heparin. Lancet 337:1425-1426, 1991.
20. Kappa JR, CA Fisher, HD Berkowitz, ED Cottrell, VP Addonizio: Heparin-induced platelet activation in sixteen surgical patients: Diagnosis and management. J Thorac Cardiovasc Surg 5:101-107, 1987.
21. Ortel TL, JP Gockerman, RM Califf, RL McCann, CM O'Connor, DM Metzler, CS Greenberg: Parenteral anticoagulation with the heparinoid Lomoparan (Org 10172) in patients with heparin induced thrombocytopenia and thrombosis. Thromb Haemostas 67:292-296, 1992.
22. Gouault-Heilmann M, D Payen, G Contant, L Intrator, Y Huet, A Schaeffer: Thrombocytopenia related to synthetic heparin analogue therapy. Thromb Haemostas 54:557 (Letter), 1985.
23. Pifarré R, JM Walenga, MJ Koza, D Hoppensteadt, TV Shankey: Studies on platelet activation in native blood by multiparametric flow cytometry. Thromb Haemostas 73:1001 (Abstract #391, p. 1001), 1995.
24. Chamberlin JR, B Lewis, F Leya, D Wallis, H Messmore, D Hoppensteadt, JM Walenga, S Moran, J Fareed, T McKiernan: Successful treatment of heparin-associated thrombocytopenia and thrombosis using hirulog. Can J Cardiol 11:511-514, 1995.
25. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators: A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 335:775-782, 1996.
26. Schwarz RP Jr: Update on the clinical development of Novastan® (argatroban): A small-molecule direct thrombin inhibitor. In: Zavoico G (Ed): Advances in Anticoagulant & Antithrombotic Drugs, IBC Biomedical Library Series, International Business Communication, Inc., Southborough, MA, 1996.
27. Walenga JM, MJ Koza, Y Khenkina, C Blakcmore, BE Lewis, R Pifarré: Coagulation assessment and laboratory monitoring of patients given the thrombin inhibitor Novastan. Blood 86(Suppl 1): 891 (Abstr #3551), 1995.
28. Koza MJ, JM Walenga, DA Hoppensteadt, EW Bermes Jr, J Fareed: Measurement of the anticoagulant effect of warfarin in the presence of an antithrombin agent using an amidolytic factor X assay. Clin Chem 42:S195 (Abstr #412), 1996.
29. Lewis BE, RC Rao, JA Robinson, D Wallis, JM Walenga, J Fareed, J Donkin, T McKiernan: Early plasmapheresis reduces mortality in patients with heparin-induced thrombosis. Blood 86 (Suppl 1):919 (Abstr), 1995.
30. Lewis BE, ED Grassman, SA Johnson, TL McKiernan: Pilot study of argatroban for angioplasty in patients with heparin allergy. Circulation 84(Suppl 1):I-375, 1996.
31. Iqbal O, B Lewis, Y Mousa, D Hoppensteadt, J Fareed, R Schwur/: Monitoring of the anticoagulant effects of argatroban during coronary angioplasty and stenting using a point of care dry reagent test card system and its comparison with ACTs (HemoTec and Hemochron). Blood 88(Suppl 1):82b (Abstr #3057), 1996.
32. Rao RC, BE Lewis, SA Johnson: Thrombolytic experience for treatment of thrombosis in patients with post-operative heparin-induced thrombocytopenia. Blood 86(Suppl 1):551 (Abstr #2190), 1995.
33. Cohen JI, MR Cooper, CS Greenberg: Streptokinase therapy of pulmonary emboli with heparin-associated thrombocytopenia. Arch Intern Med 135:1725-1726, 1985.
34. Fiessinger JN, M Aiach, M Roncato, C Debure, JC Gaux: Critical ischemia during heparin-induced thrombocytopenia. Treatment by intra-arterial Streptokinase. Thromb Res 33:235-238, 1984.
35. Antman EM, for the TIMI 9B Investigators: Hirudin in acute myocardial infarction. Circulation 94:911-921, 1996.